Vaccination against cytomegalovirus.
Like varicella zoster virus (VZV), human cytomegalovirus (HCMV) causes disease after both primary and recurrent infections. The former is more serious, particularly in pregnant women, who may transmit the virus to their offspring, with a high risk of mental retardation and deafness. Various experimental vaccines are in development, ranging from live, attenuated HCMV, subunit envelope glycoprotein, poxvirus vectors with CMV genes inserted, and plasmid DANN.
Plotkin
S A
SA
University of Pennsylvania Wistar Institute, Doylestown, USA.
D000818:Animals; D018150:Avipoxvirus / Q000235:genetics; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000517:prevention & control; D022482:Cytomegalovirus Vaccines / Q000276:immunology*; D004279:DNA, Viral; D006801:Humans; D010957:Plasmids; D011995:Recombination, Genetic; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology
D022482:Cytomegalovirus Vaccines; D004279:DNA, Viral; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; C040495:glycoprotein B, Simplexvirus; C071440:glycoprotein H, Cytomegalovirus; C499358:glycoprotein H, Human cytomegalovirus